Type 2 diabetes is a disease characterised by high blood sugar levels. The World Health Organisation (WHO) estimates that by 2040, 642 million people worldwide will suffer from diabetes. Alternatives such as Amaranth (Amaranthus hypochondriacus), a plant endemic to Mexico, have been shown to have a hypoglycaemic effect in some preclinical studies based on protein fractions. However, in this study, the effect of amaranth total protein hydrolysates was evaluated in a preclinical animal model (Wistar rat) and in a clinical pilot phase in healthy people, under the prior approval of the Research Ethics Committee of Investigación Biomédica para el Desarrollo de Fármacos S. A. de C.V. Protein isolate was prepared from flour and hydrolysed at pH 7.3 at 55 °C for 3 and 6 h with alkalase (0.8 AU/ml), the degree of hydrolysis (GH) was determined and the molecular weight of the hydrolysates was resolved by mass exclusion chromatography. The isolate contained 80-87 % protein, the GH for the 6 and 3 h digests was 11-14 % GH, respectively. The administration of the hydrolysate for 6 h at 300 mg/kg body weight in the animal model (n=15) had an effect and significance of differences between treatments with Tukey tests at p<0.05, while in the pilot test in humans (n=5) starting with 900 mg/kg hydrolysate for 3 h, an effect with a hypoglycaemic tendency was observed 30 min after ingestion with a p= 0. 188 according to the Wilconxon test; concentrations, GH, and time are still being analysed in order to maintain constant control of serum glucose, as was achieved in animals, and to obtain an amaranth-based product with hypoglycaemic bioactives.